Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
1. Amgen and Kyowa report positive ASCEND study results for rocatinlimab. 2. Rocatinlimab targets OX40 receptor for treating atopic dermatitis. 3. Long-term efficacy and safety evaluated over 104 weeks. 4. Most patients experienced continued therapeutic benefit at one year. 5. Full results to be shared at upcoming congress or publication.